Biogen's Vumerity Receives EU Approval for Relapsing-Remitting Multiple Sclerosis
Enters Commercialization Phase with EU Approval
On November 15, 2021, the European Commission approved Vumerity (diroximel fumarate) from Biogen Inc. (BIIB) as a treatment for relapsing-remitting multiple sclerosis (RRMS) in adults. This follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) on September 16, 2021, marking the final marketing authorization. This approval allows Biogen to initiate pricing and reimbursement negotiations across EU member states without repeating the approval process in each country. However, the actual rate of adoption will depend on health technology assessments and insurance coverage criteria in each country.
Nrf2-Based Oral Fumarate
Vumerity's generic name is diroximel fumarate (BIIB098), which is rapidly converted in the body to its active metabolite, monomethyl fumarate (MMF). MMF activates the nuclear factor erythroid 2-related factor 2 (Nrf2/NFE2L2) pathway, which regulates the response to oxidative stress, and this pathway is presented as the pharmacological key target. The EMA approval was based on pharmacokinetic data demonstrating equivalent MMF exposure to dimethyl fumarate, and a bridging strategy linking this to the existing clinical data for Tecfidera (dimethyl fumarate). A study of 1,234 patients cited by the EMA showed that the proportion of patients with relapses within two years was 27% for dimethyl fumarate and 46% for placebo.
Gastrointestinal Tolerability is Key, Rather Than Efficacy Differentiation
The direct competitive benchmark is Biogen's Tecfidera and its generics, which generate the same active metabolite. Other oral standard treatments include Aubagio (teriflunomide) from Sanofi and Mavenclad (cladribine) from Merck KGaA. In the high-efficacy treatment group, Ocrevus (ocrelizumab) from Roche and Kesimpta (ofatumumab) from Novartis compete for patient selection. The commercial rationale for Vumerity lies in maintaining the proven efficacy of fumarates while improving gastrointestinal tolerability compared to Tecfidera, rather than introducing a new mechanism of action. Therefore, actual adherence rates and reimbursement agency evaluations, which justify a higher price than generic dimethyl fumarate, are key variables.
U.S. Approval and Transaction Structure Support the Product
The U.S. Food and Drug Administration (FDA) approved Vumerity as a treatment for relapsing multiple sclerosis in adults on October 29, 2019, without a separate advisory committee (AdComm) vote, and the approved indication is broader than in the EU. In 2017, Biogen secured exclusive global development and commercialization rights for BIIB098 from Alkermes plc (ALKS) and agreed to pay a pre-payment of $28 million and up to $200 million in milestone payments, plus a royalty in the mid-teens percentage of global net sales. The FDA approval triggered a payment of $150 million. Global sales of multiple sclerosis treatments were $32.8 billion in 2024, and Vumerity's global sales in 2025 were $746.8 million, an increase of 18.9% year-on-year, demonstrating that the EU approval has translated into actual commercial value.
The EU approval has transformed Vumerity from a development pipeline asset into a marketed product, providing a regulatory foundation for defending Biogen's aging multiple sclerosis franchise. In a global market of $32.8 billion in 2024, sales of $746.8 million in 2025 and a growth rate of 18.9% demonstrate that demand has expanded even with the erosion of Tecfidera generics. From a research perspective, the bridging strategy, which shares the Nrf2/NFE2L2 pathway and MMF exposure, is significant as it represents a case where approval was achieved without repeating late-stage clinical trials. Medium- to long-term market share will be determined by the price pressure from Tecfidera generics and other oral agents, the efficacy/convenience positioning compared to CD20 high-efficacy treatments such as Ocrevus and Kesimpta, and the reimbursement conditions in each European country. Alkermes still has up to $200 million in milestone payments and a royalty in the mid-teens percentage of net sales, so an increase in prescriptions will be reflected differently in the value of both companies.
Source: EMA (ema)